866-997-4948(US-Canada Toll Free)

Non- Small Cell Lung Cancer - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Sep 2012

Category :

Cancer

No. of Pages : 756 Pages


Non-Small Cell Lung Cancer Pipeline Review, H2 2012

Global Markets Directs, \'Non-Small Cell Lung Cancer Pipeline Review, Global Markets Directs, \'Non-Small Cell Lung Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. 

Non-Small Cell Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
  • A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Content

List of Tables 
List of Figures 
Introduction 
Global Markets Direct Report Coverage 
Non-Small Cell Lung Cancer Overview 
Therapeutics Development 
An Overview of Pipeline Products for Non-Small Cell Lung Cancer 
Non-Small Cell Lung Cancer Therapeutics under Development by Companies 
Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 
Late Stage Products 
Comparative Analysis 
Mid Clinical Stage Products 
Comparative Analysis 
Early Clinical Stage Products 
Comparative Analysis 
Discovery and Pre-Clinical Stage Products 
Comparative Analysis 
Non-Small Cell Lung Cancer Therapeutics – Products under Development by Companies 
Non-Small Cell Lung Cancer Therapeutics – Products under Investigation by Universities/Institutes 
Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development 
Bristol-Myers Squibb Company 
Johnson & Johnson 
Boehringer Ingelheim GmbH 
F. Hoffmann-La Roche Ltd. 
Kyowa Hakko Kirin Co., Ltd. 
Abbott Laboratories 
Biogen Idec Inc. 
Amgen Inc. 
Sanofi-Aventis 
AstraZeneca PLC 
Eli Lilly and Company 
GlaxoSmithKline plc 
Genentech, Inc. 
Antigenics, Inc. 
Isis Pharmaceuticals, Inc. 
Daiichi Sankyo Company, Ltd 
Merck & Co., Inc. 
Infinity Pharmaceuticals, Inc. 
YM BioSciences Inc. 
Aposense Ltd. 
ZIOPHARM Oncology, Inc. 
Millennium Pharmaceuticals, Inc. 
Novartis AG 
Samyang Corporation 
ImClone Systems Incorporated 
Astellas Pharma Inc. 
Biocon Limited 
Cephalon, Inc. 
Chong Kun Dang Pharmaceutical 
Chugai Pharmaceutical Co. Ltd 
Eisai Co., Ltd. 
Human Genome Sciences, Inc. 
ImmunoGen, Inc. 
Ono Pharmaceutical Co., Ltd. 
OSI Pharmaceuticals, Inc. 
Pfizer Inc. 
Taiho Pharmaceutical Co., Ltd. 
Teva Pharmaceutical Industries Limited 
Yakult Honsha Co., Ltd. 
Santaris Pharma A/S 
Exelixis, Inc. 
Aduro BioTech 
Cyclacel Pharmaceuticals Inc. 
Alfacell Corporation 
Celgene Corporation 
Bayer AG 
Geron Corporation 
SRI International 
Aeolus Pharmaceuticals, Inc. 
Merck KGaA 
EntreMed, Inc. 
Hana Biosciences, Inc. 
Celldex Therapeutics, Inc. 
Idera Pharmaceuticals, Inc. 
Ariad Pharmaceuticals, Inc. 
Lorus Therapeutics Inc 
Benitec Ltd. 
MethylGene Inc 
GANYMED Pharmaceuticals AG 
Ora Bio Ltd. 
Philogen S.p.A. 
NovaRx Corporation 
Acceleron Pharma, Inc. 
Vaxon Biotech 
CureVac GmbH 
Nereus Pharmaceuticals, Inc. 
AVEO Pharmaceuticals, Inc. 
Medisyn Technologies, Inc. 
Advanced Cancer Therapeutics 
Pique Therapeutics 
Clovis Oncology, Inc. 
SAIC-Frederick, Inc. 
Nippon Medical Research, Inc. 
Medical Enzymes AG 
KAEL-GemVax 
BetaPharma, Inc. 
Mebiopharm Co., Ltd. 
Agennix AG 
Regulon Inc. 
Kansai Medical University 
Optimum Therapeutics, LLC 
PharmaTech International, Inc. 
Non-Small Cell Lung Cancer – Therapeutics Assessment 
Assessment by Monotherapy Products 
Assessment by Combination Products 
Assessment by Route of Administration 
Assessment by Molecule Type 
Drug Profiles 
Halaven - Drug Profile 
Motesanib - Drug Profile 
filgrastim + sargramostim + cyclophosphamide + melphalan - Drug Profile 
Necitumumab - Drug Profile 
Nexavar - Drug Profile 
Erbitux - Drug Profile 
Stimuvax - Drug Profile 
RG3638 - Drug Profile 
Sotatercept - Drug Profile 
PF-00299804 - Drug Profile 
Xalkori - Drug Profile 
Afatinib - Drug Profile 
Paclitaxel + Carboplatin + Bevacizumab - Drug Profile 
Afatinib + Taxol - Drug Profile 
Tavocept + Cisplatin + Docetaxel - Drug Profile 
Tarceva + MetMAb - Drug Profile 
Abraxane + Carboplatin - Drug Profile 
Cetuximab + Pemetrexed - Drug Profile 
Cetuximab + Docetaxel - Drug Profile 
Alimta + Cisplatin + Gefitinib - Drug Profile 
Vargatef + Docetaxel - Drug Profile 
BSI-201 + Gemcitabine + Carboplatin - Drug Profile 
Carboplatin + Paclitaxel + Rebimastat - Drug Profile 
Vargatef + Pemetrexed - Drug Profile 
GSK1572932A - Drug Profile 
Erlotinib - Drug Profile 
Docetaxel + Carboplatin - Drug Profile 
Docetaxel - Drug Profile 
Docetaxel + S-1 - Drug Profile 
Platinum Based Chemotherapy + Zoledronic Acid - Drug Profile 
Gefitinib - Drug Profile 
Carboplatin + Paclitaxel - Drug Profile 
Taxotere - Drug Profile 
Bevacizumab + Pemetrexed - Drug Profile 
ARQ197 + Erlotinib - Drug Profile 
Cisplatin + Docetaxel + Irinotecan - Drug Profile 
Carboplatin + TS-1 - Drug Profile 
Lipoplatin - Drug Profile 
Ganetespib + Docetaxel - Drug Profile 
Carboplatin + Radiation Therapy - Drug Profile 
Tarceva - Drug Profile 
Liposomal Cisplatin + Paclitaxel - Drug Profile 
IMC-1121B + Docetaxel - Drug Profile 
Apatinib - Drug Profile 
Paclitaxel - Drug Profile 
Talactoferrin + Carboplatin + Paclitaxel - Drug Profile 
Endostar + Vinorelbine + Cisplatin - Drug Profile 
Acetylcarnitine + Cisplatin - Drug Profile 
Cetuximab + Paclitaxel + Carboplatin + Bevacizumab - Drug Profile 
Non-Small Cell Lung Cancer Therapeutics – Drug Profile Updates 
Non-Small Cell Lung Cancer Therapeutics – Discontinued Products 
Non-Small Cell Lung Cancer Therapeutics - Dormant Products 
Non-Small Cell Lung Cancer – Product Development Milestones 
Featured News & Press Releases 

Appendix 
Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 

List of Table


Number of Products Under Development for Non-Small Cell Lung Cancer, H2 2012 36
Products under Development for Non-Small Cell Lung Cancer Comparative Analysis, H2 2012 37
Number of Products under Development by Companies, H2 2012 39
Number of Products under Development by Companies, H2 2012 (Contd..1) 40
Number of Products under Development by Companies, H2 2012 (Contd..2) 41
Number of Products under Development by Companies, H2 2012 (Contd..3) 42
Number of Products under Development by Companies, H2 2012 (Contd..4) 43
Number of Products under Development by Companies, H2 2012 (Contd..5) 44
Number of Products under Development by Companies, H2 2012 (Contd..6) 45
Number of Products under Development by Companies, H2 2012 (Contd..7) 46
Number of Products under Development by Companies, H2 2012 (Contd..8) 47
Number of Products under Development by Companies, H2 2012 (Contd..9) 48
Number of Products under Development by Companies, H2 2012 (Contd..10) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 59
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 60
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 61
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 62
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 63
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 64
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 65
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 66
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 67
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 68
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 69
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 70
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 71
Comparative Analysis by Late Stage Development, H2 2012 72
Comparative Analysis by Mid Clinical Stage Development, H2 2012 73
Comparative Analysis by Early Clinical Stage Development, H2 2012 74
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 75
Products under Development by Companies, H2 2012 76
Products under Development by Companies, H2 2012 (Contd..1) 77
Products under Development by Companies, H2 2012 (Contd..2) 78
Products under Development by Companies, H2 2012 (Contd..3) 79
Products under Development by Companies, H2 2012 (Contd..4) 80
Products under Development by Companies, H2 2012 (Contd..5) 81
Products under Development by Companies, H2 2012 (Contd..6) 82
Products under Development by Companies, H2 2012 (Contd..7) 83
Products under Development by Companies, H2 2012 (Contd..8) 84
Products under Development by Companies, H2 2012 (Contd..9) 85
Products under Development by Companies, H2 2012 (Contd..10) 86
Products under Development by Companies, H2 2012 (Contd..11) 87
Products under Development by Companies, H2 2012 (Contd..12) 88
Products under Development by Companies, H2 2012 (Contd..13) 89
Products under Development by Companies, H2 2012 (Contd..14) 90
Products under Development by Companies, H2 2012 (Contd..15) 91
Products under Development by Companies, H2 2012 (Contd..16) 92
Products under Development by Companies, H2 2012 (Contd..17) 93
Products under Development by Companies, H2 2012 (Contd..18) 94
Products under Development by Companies, H2 2012 (Contd..19) 95
Products under Development by Companies, H2 2012 (Contd..20) 96
Products under Development by Companies, H2 2012 (Contd..21) 97
Products under Development by Companies, H2 2012 (Contd..22) 98
Products under Development by Companies, H2 2012 (Contd..23) 99
Products under Development by Companies, H2 2012 (Contd..24) 100
Products under Investigation by Universities/Institutes, H2 2012 101
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 102
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 103
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 104
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 105
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 106
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 107
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 108
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 109
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 110
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 111
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 112
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 128
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 129
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 130
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 131
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 132
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 133
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 134
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 135
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 136
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 137
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 138
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 139
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 140
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 141
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 142
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 145
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..46) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..47) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..48) 149
Products under Investigation by Universities/Institutes, H2 2012 (Contd..49) 150
Products under Investigation by Universities/Institutes, H2 2012 (Contd..50) 151
Products under Investigation by Universities/Institutes, H2 2012 (Contd..51) 152
Products under Investigation by Universities/Institutes, H2 2012 (Contd..52) 153
Products under Investigation by Universities/Institutes, H2 2012 (Contd..53) 154
Products under Investigation by Universities/Institutes, H2 2012 (Contd..54) 155
Products under Investigation by Universities/Institutes, H2 2012 (Contd..55) 156
Products under Investigation by Universities/Institutes, H2 2012 (Contd..56) 157
Products under Investigation by Universities/Institutes, H2 2012 (Contd..57) 158
Products under Investigation by Universities/Institutes, H2 2012 (Contd..58) 159
Bristol-Myers Squibb Company, H2 2012 160
Boehringer Ingelheim GmbH, H2 2012 161
F. Hoffmann-La Roche Ltd., H2 2012 162
Kyowa Hakko Kirin Co., Ltd., H2 2012 163
Abbott Laboratories, H2 2012 164
Biogen Idec Inc., H2 2012 165
Helix BioPharma Corp., H2 2012 166
Amgen Inc., H2 2012 167
Sanofi-Aventis, H2 2012 168
AstraZeneca PLC, H2 2012 169
Eli Lilly and Company, H2 2012 170
GlaxoSmithKline plc, H2 2012 172
Genentech, Inc., H2 2012 173
Antigenics, Inc., H2 2012 174
Inovio Biomedical Corporation, H2 2012 175
MedImmune LLC, H2 2012 176
Isis Pharmaceuticals, Inc., H2 2012 177
Daiichi Sankyo Company, Ltd, H2 2012 178
Merck & Co., Inc., H2 2012 179
Infinity Pharmaceuticals, Inc., H2 2012 180
Takeda Pharmaceutical Company Limited, H2 2012 181
YM BioSciences Inc., H2 2012 182
Celltrion, Inc., H2 2012 183
ZIOPHARM Oncology, Inc., H2 2012 184
Millennium Pharmaceuticals, Inc., H2 2012 185
Novartis AG, H2 2012 186
Astellas Pharma Inc., H2 2012 187
Biocon Limited, H2 2012 188
Cephalon, Inc., H2 2012 189
Chong Kun Dang Pharmaceutical, H2 2012 190
Chugai Pharmaceutical Co. Ltd, H2 2012 191
Eisai Co., Ltd., H2 2012 192
Human Genome Sciences, Inc., H2 2012 193
OSI Pharmaceuticals, Inc., H2 2012 194
Pfizer Inc., H2 2012 195
Taiho Pharmaceutical Co., Ltd., H2 2012 196
Teva Pharmaceutical Industries Limited, H2 2012 197
Yakult Honsha Co., Ltd., H2 2012 198
Cell Therapeutics, Inc., H2 2012 199
Exelixis, Inc., H2 2012 200
Aduro BioTech, H2 2012 201
Cyclacel Pharmaceuticals Inc., H2 2012 202
Alfacell Corporation, H2 2012 203
Celgene Corporation, H2 2012 204
Onyx Pharmaceuticals, Inc., H2 2012 205
Bayer AG, H2 2012 206
Geron Corporation, H2 2012 207
Aeolus Pharmaceuticals, Inc., H2 2012 208
Merck KGaA, H2 2012 209
EntreMed, Inc., H2 2012 210
Hana Biosciences, Inc., H2 2012 211
Celldex Therapeutics, Inc., H2 2012 21

List of Chart


Number of Products under Development for Non-Small Cell Lung Cancer, H2 2012 36
Products under Development for Non-Small Cell Lung Cancer Comparative Analysis, H2 2012 37
Products under Development by Companies, H2 2012 38
Products under Investigation by Universities/Institutes, H2 2012 50
Late Stage Products, H2 2012 72
Mid Clinical Stage Products, H2 2012 73
Early Clinical Stage Products, H2 2012 74
Discovery and Pre-Clinical Stage Products, H2 2012 75
Assessment by Monotherapy Products, H2 2012 310
Assessment by Combination Products, H2 2012 311
Assessment by Route of Administration, H2 2012 312
Assessment by Stage and Route of Administration, H2 2012 313
Assessment by Molecule Type, H2 2012 314
Assessment by Stage and Molecule Type, H2 2012 315

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *